The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index; 13 of the 34 sources its claims cite were checked for support.
Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study
Open accessAbstract
Background: Tapering strips facilitate antidepressant discontinuation, allowing for personalised titration of discontinuation to the intensity of withdrawal. A tapering strip consists of antidepressant or other medication, packaged in a 28-day roll of daily pouches, each with the same or slightly lower dose than the one before. Previous studies demonstrated 70% real-world effectiveness of tapering strips. Here, we present a third, questionnaire-based retrospective cohort study in a large sample. Methods: Patients whose doctor had prescribed tapering strips between October 2015 and December 2018 were sent a questionnaire for participation after completion of tapering between December 2015 and January 2020. Of 1240 individuals who returned a questionnaire (response rate: 59%), 987 (80%) used an antidepressant, of whom 824 (83%) had wished to discontinue their antidepressant. Results: The sample was demographically representative of antidepressant users in the Netherlands. Less than 40% of participants had heard of tapering strips through their clinicians – Internet was the most frequent source. Of the 824 individuals, 341 (41%) had used strips for tapering venlafaxine, 206 (25%) for paroxetine and 277 (34%) for other antidepressants. Median duration of antidepressant use was 5–10 years, and most (71%) had tried to come off without tapering strips at least once. Most patients (72%) were able to discontinue their antidepressant, using a median of two strips to taper over a median period of 56 days. Females and individuals with (1) more severe experience of withdrawal during the use of tapering strips, (2) more years of use of antidepressant medication and (3) more previous attempts at discontinuation were less likely to be able to discontinue their antidepressant medication with tapering strips. Conclusion: The results of this study validate, for the third time, the observation that tapering strips can address the problem of antidepressant withdrawal symptoms in individuals attempting to discontinue antidepressants.
Overview
CoChat Summary
TL;DR
In a retrospective questionnaire cohort of 824 Dutch antidepressant users prescribed tapering strips, 72% reported discontinuing their antidepressant, using a median of two strips over a median of 56 days. Longer antidepressant use, female sex, more withdrawal during tapering, and antidepressants other than venlafaxine were associated with lower odds of successful tapering.
Key findings
- Successful tapering was reported by 72% (568/824; 31 missing values); participants used a median of 2 tapering strips over a median of 56 days.
- The sample was demographically representative of adult antidepressant users in the Netherlands (mean age 49.5 years; 75% female; NEMESIS-2 comparison: mean age 49.5 years, 69% female). Tapering was for venlafaxine in 41%, paroxetine in 25%, and other antidepressants in 34%; 71% had previously tried to come off without tapering strips.
- In univariable logistic regression, lower odds of successful tapering were associated with female sex (OR = 0.672, 95% CI: 0.462–0.978), longer duration of use (OR linear trend = 0.694, 95% CI: 0.603–0.798), more previous attempts (OR linear trend = 0.824, 95% CI: 0.725–0.937), more withdrawal with tapering strips (OR linear trend = 0.825, 95% CI: 0.733–0.928), paroxetine versus venlafaxine (OR = 0.496, 95% CI: 0.335–0.737), and other antidepressant versus venlafaxine (OR = 0.611, 95% CI: 0.423–0.886).
- In multivariable regression, associations were retained for female sex (OR = 0.502, 95% CI: 0.284–0.886), duration of use (OR linear trend = 0.618, 95% CI: 0.494–0.774), withdrawal with tapering strips (OR = 0.851, 95% CI: 0.751–0.963), and other antidepressant versus venlafaxine (OR = 0.508, 95% CI: 0.305–0.846); previous attempts and paroxetine were not retained.
Methods
- Retrospective questionnaire-based cohort: patients prescribed tapering strips between October 2015 and December 2018 were invited after completing tapering between December 2015 and January 2020; 1240 returned questionnaires (response rate 59%), 987 (80%) used an antidepressant, and 824 (83%) wished to discontinue and were included.
- Variables included age, sex, medication type and duration, previous discontinuation attempts, withdrawal severity on 1–7 Likert scales, tapering quality on 1–7 Likert scales, and whether the individual tapered off completely; the main outcome was “successful tapering” (off medication after completion of tapering strips).
- Univariable and multivariable logistic regression yielded odds ratios and 95% confidence intervals; age and sex distribution were compared with the NEMESIS-2 sample, and no large or significant interactions with antidepressant categories were found.
Limitations
- Stated: the sample was largely selected by referring physicians for unsuccessful previous tapering and chronic antidepressant use, so the 72% success rate applies to a group considered most at risk of severe withdrawal; around 60% responded, with possible selective non-response bias.
- Stated: the brief quality-assurance questionnaire limited more precise assessment of variables such as relapse type, prescriber support, total tapering trajectory length, and current symptoms; withdrawal assessment was subjective, and recall of previous withdrawal may have been influenced by the more recent tapering-strip experience.
- Evident: this was an uncontrolled, retrospective, self-report cohort without a randomized or usual-care comparison arm, so causal conclusions about tapering strips cannot be drawn; the paper also notes no follow-up after tapering in the current study, only the tapering period and outcome.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
10 Valid · 1 Not valid · 15 Not checked · 47 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Of participants who had tapered successfully using tapering strips, 72% was still without antidepressant 1–5 years later (follow-up data study 2)21.”
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Discussion > Findings
What the sources say
- Disputedcites [21] Groot PC van Os J. Outcome of antidepressant drug discontinuation with taperingstrips after 1-5 years. Ther Adv Psychopharmacol 2020; 10: 2045125320954609. 32953040 PMC7476339 sourceExperimental — accuracy not yet measured
Our copy reports the 1–5 year outcome as 66% (270/408) still off antidepressants, with a dichotomous success rate of 68% (276/408) when the 6 people on a reduced dose are included (Results; Abstract Results; Table 3 total 67.6%) — no 72% figure for this outcome appears anywhere in the paper (the only 72% is 72.3% female in the venlafaxine row of Table 3). The Discussion 'Findings' and Conclusion explicitly frame the long-term rate as 68%, matching the earlier 71% short-term rate, so the attributed magnitude is contrary to what the source states. The denominator also differs: the paper's rate is computed over all 408 who attempted tapering, not over a subset who had already tapered successfully, and the Methodological issues section states the researchers could not identify prior short-term-study participants. (LLM, conf=0.72)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“there is consensus that users of antidepressants and especially of SSRIs (Selective serotonin reuptake inhibitors) and SNRIs (Serotonin and norepinephrine reuptake inhibitors) often experience difficulties coming off medication.1,2”
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Introduction
What the sources say
- Supportedcites [1] Davies J Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: are guidelines evidence-based. Addict Behav 2019; 97: 111– 121. 30292574 source
The Introduction (p. 1) states that 'antidepressants have been long known to induce withdrawal reactions in a large proportion of users' and that in some people these reactions are 'severe, long-lasting and can make normal functioning impossible', and it quotes the SNRI systematic review that 'Withdrawal symptoms occurred after discontinuation of any type of SNRI'. Section 3.2 (Incidence) pools 14 SSRI/SNRI-centred studies giving a weighted average withdrawal incidence of 55.7% (2258/4052), i.e. 'often'; Table 1 shows the highest rates for paroxetine and venlafaxine, supporting the 'especially SSRIs and SNRIs' emphasis, and §4.3 reports users' testimonies of the difficulty of getting off. The paraphrase matches what this review says. (LLM, conf=0.88)
- Supportedcites [2] Fava GA Benasi G Lucente M, et al Withdrawal symptoms after serotonin-noradrenaline reuptake inhibitor discontinuation: systematic review. Psychother Psychosom 2018; 87: 195– 203. 30016772 source
The Introduction (p. 1) states that withdrawal symptoms have been reported after reduction/discontinuation of antidepressants including SSRI and SNRI, and that a systematic review documented such manifestations as withdrawal reactions that 'frequently occur even with gradual tapering', with SNRI producing similar symptomatologies. The Discussion (p. 5) adds that withdrawal symptoms occurred regardless of whether discontinuation was gradual or abrupt, and the Results (p. 5) describe discontinuation symptoms causing significant social/occupational impairment. The citing sentence's word 'consensus' is the authors' framing rather than a term used in our copy (which in fact disputes the label 'discontinuation syndrome'), but the substantive content attributed — that antidepressant users, especially of SSRIs and SNRIs, commonly have difficulty coming off medication — is stated in our copy. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The results of this study are remarkably similar to those of two previous studies.20,21”
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Discussion > Findings
What the sources say
- Not checked yetcites [20] Groot PC van Os J. Antidepressant tapering strips to help people come off medication more safely. Psychosis 2018; 10: 142– 145. source
- Supportedcites [21] Groot PC van Os J. Outcome of antidepressant drug discontinuation with taperingstrips after 1-5 years. Ther Adv Psychopharmacol 2020; 10: 2045125320954609. 32953040 PMC7476339 source
The citation is attached to the identification of a previous study whose antidepressant-discontinuation results the citing authors compare with their own. Our copy of Groot & van Os (2020) is exactly such a prior study: the Abstract Conclusion states that the previously reported 71% short-term success rate of taperingstrips 'was matched by a 68% rate after 1–5 years', and the Results (Table 3 narrative) report dichotomous success of n = 276 (68%) among 408 antidepressant users. The Discussion (Findings) likewise frames its results as replicating earlier work on tapering strips. The judgement that these results are 'remarkably similar' to the citing study's own is the citing authors' conclusion and is not content attributable to this source; nothing in our copy contradicts it. (LLM, conf=0.80)
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“number of previous attempts (OR linear trend = 0.824, 95% CI: 0.725–0.937)”
- Also stated in: § Results · plain
“The proportion of successful tapers was lower with more previous attempts (76% first attempters versus 57% in those with more than three attempts; Table 5).”
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Results > Risk factors
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“severity of withdrawal with tapering strips (OR linear trend = 0.825, 95% CI: 0.733–0.928)”
- Also stated in: § Risk factors · plain
“Level of withdrawal experienced with tapering stripd | 0.851 | 0.011 | 0.751 | 0.963”
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Results > Risk factors
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on 2 assumptions not shown here.
- Also stated in: § Risk factors · plain
29 more claims
Create a free account to see all 73 claims and to verify the 21 references still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The fact that they were by far the most common antidepressants that tapering strips were requested for in this and previous surveys23,26,27 suggests, given over-representation in the study group relative to overall prescription rates, that use of these medications is associated with greater risk of withdrawal, as widely recognised”
From Outcomes of hyperbolic tapering of antidepressants (2023) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, preliminary data from non-randomised trials suggest that hyperbolic tapering through tapering strips may reduce the incidence of withdrawal symptoms.”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the absence of RCTs, tapering guidance could be informed by other types of evidence such as non-randomised and retrospective studies of tapering strips,17,18 pharmacologically rational theory on withdrawal symptoms and dose-reduction regimens,12,49 patients’ experiences of undergoing withdrawal, 50 and expert knowledge, 51 which could be synthesised for that purpose.”
From Clinical practice guideline recommendations on tapering and discontinuing antidepressants for depression: a systematic review (2022) · cites this paper as [18]
In the citing paper
“There was no overlap between the current sample and three previous samples we reported on previously.23,26,27”
From Outcomes of hyperbolic tapering of antidepressants (2023) · cites this paper as [26]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“the probability of successful stopping was reduced multiplicatively by a factor 0.694, that is, a factor 0.232 between lowest and the highest category”
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Results > Risk factors
Reported 0.232 · recomputed 0.754117
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“the probability of successful stopping was reduced multiplicatively by a factor 0.824, that is, a factor 0.461 between lowest and the highest category”
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Results > Risk factors
Reported 0.461 · recomputed 0.747096
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Results
“The proportion of females was higher in the group whose tapering trajectory was not successful (77%) compared to those tapering successfully (70%)”
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Results
“| No success | Mean | 49.73 | 6 | 3.54 | 76.75 | 2.74 | 80% | 26% |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Introduction
“a non-overlapping sample of 824 patients who used tapering strips to discontinue their antidepressant medication”
§ Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study > Results
“| | Min | 20 | 1 | 1 | 0 | 0 | | |”
Citations
Cites
Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs
Concato, J., Shah, N., & Horwitz, R. I. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422507 · Cited by 3,563
Holm, J. C., Nowicka, P., Farpour-Lambert, N. J., O'Malley, G., Hassapidou, M., Weiss, R., & Baker, J. L. (2014) · Obesity Facts · doi:10.1159/000365773 · Cited by 592
Randomized Trials or Observational Tribulations?
Pocock, S. J., & Elbourne, D. R. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006223422511 · Cited by 550
Critical Slowing Down as a Personalized Early Warning Signal for Depression
Wichers, M., Groot, P. C., & Psychosystems, E. G. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000441458 · Cited by 399
Self-citationDavies, J., & Read, J. (2019) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.08.027 · Cited by 387
Tapering of SSRI treatment to mitigate withdrawal symptoms
Horowitz, M. A., & Taylor, D. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30032-x · Cited by 280
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209 · cited 2×
“Variables collected were: (1) age (in years), (2) sex, (3) type of medication and duration of use prior to tapering, (4) number of attempts to stop medication before using tapering strips, (5) severity of withdrawal symptoms during previous discontinuation attempts without tapering strips on a 1–7 Likert scale (‘Did y…”
BackgroundThe Netherlands Mental Health Survey and Incidence Study‐2 (NEMESIS‐2): design and methods
de Graaf, R., ten Have, M., & van Dorsselaer, S. (2010) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.317 · Cited by 200
Read, J., & Williams, J. (2018) · Current Drug Safety · doi:10.2174/1574886313666180605095130 · Cited by 175
A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse
Horowitz, M. A., Jauhar, S., Natesan, S., Murray, R. M., & Taylor, D. (2021) · Schizophrenia Bulletin · doi:10.1093/schbul/sbab017 · Cited by 157
Research works printed but not linked: 1
- Van Leeuwen E, 2021, Cochrane Database Syst Rev, 4
Cited by
Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis
Henssler, J., Schmidt, Y., Schmidt, U., Schwarzer, G., Bschor, T., & Baethge, C. (2024) · The Lancet Psychiatry · doi:10.1016/s2215-0366(24)00133-0 · Cited by 106
Sørensen, A., Juhl Jørgensen, K., & Munkholm, K. (2022) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211067656 · Cited by 52
Outcomes of hyperbolic tapering of antidepressants
van Os, J., & Groot, P. C. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231171518 · Cited by 22
Self-citationEserian, J. K., Blanco, V. P., Mercuri, L. P., Matos, J. D. R., & Galduróz, J. C. F. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115537 · Cited by 15
Boland, M., Higgins, A., Beecher, C., Bracken, P., Burn, W., Cody, A., Framer, A., Gronlund, T., Horowitz, M., Huff, C., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-088266 · Cited by 14
Metadata
- Authors
- Groot, P. C., & van Os, J.
- Affiliations
- University Medical Center Utrecht (NL)
- Department of Psychiatry, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Postbus 85500, 3508 GA Utrecht, The Netherlands
- Venue
- Therapeutic Advances in Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2021-01
- Volume
- 11
- Pages
- 20451253211039327-20451253211039327
- ISSN
- 2045-1253 (ISSN-L)
- 2045-1261
- PMC
- PMC8404667
- OpenAlex
- W3197897999
- Cited by
- 38
- References
- 28
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 12 · 2023: 7 · 2022: 4
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Therapeutic Advances in Psychopharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
- Keywords
- antidepressant discontinuation, antidepressant withdrawal symptoms, venlafaxine, paroxetine, patient-reported outcomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. https://app.cochat.ai/papers/10.1177/20451253211039327
- The paper
- Groot, P. C., & van Os, J. (2021). Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253211039327
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
